Is vitamin D deficiency associated with the COVID-19 epidemic in Europe?

Dimitra Rafailia Bakaloudi, Michail Chourdakis
doi: https://doi.org/10.1101/2021.01.28.21250673

Abstract

Objective COVID-19 has emerged as a global pandemic, affecting nearly 80 million people from 218 countries as of December 2020. At the same time, vitamin D deficiency seems to be prevalent among COVID-19 patients. Hence, the association between the prevalence of vitamin D deficiency and COVID-19 infection and mortality among European countries was examined.

Design A case series and recent literature review study

Settings Information on prevalence of vitamin D deficiency in each country was retrieved through literature searching on PubMed® database. As of December, 23rd 2020, COVID-19 infections and mortalities per million population were extracted from the Worldometer website, whereas the latitude of each country was taken from the CSGNetwork website. The association between both vitamin D deficiency and COVID-19 infection and mortality were explored using correlation coefficients and scatterplots.

Participants European Countries-Populations

Results The range of prevalence of vitamin D deficiency among European countries was 6.9-75.1%, with most countries facing more than 50% of vitamin D deficiency among their population. Significant positive correlations were observed between COVID-19 infections (r=0.82; p<0.001) and mortalities (r=0.53; p=0.05) per million population with the prevalence of vitamin D deficiency. Most of the high latitude countries showed lower rates of COVID-19 infections and mortalities compared to middle latitude countries.

Conclusion Prevalence of vitamin D deficiency was significantly associated with both infection and mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be considered when implementing preventive measures to mitigate the mortality rate of COVID-19.

  • Vitamin D
  • deficiency
  • COVID-19
  • infections
  • mortalities
  • Europe

Introduction

COVID-19 has become a global public health emergency, affecting more than 80 million people from 218 countries and territories(1) in less than a year since the very first outbreak in Wuhan, China(2). As of December, 23rd 2020, the lowest and highest number of confirmed cases per one million (1M) population, were reported among Oceanic (1380/1M) and North American (36,276/1M) continents respectively(3). This substantial variation in the number of infections and as well as the severity and mortality of the disease can be accredited to several factors both at the state level as well as at an individual level. “State level” parameters include diverse factors, such as a country’s preparedness, actions of the governments, health infrastructure, timing of lockdown, rapid border closures, implementation of social distancing and socioeconomic status(4), while the “individual level” includes the sociodemographic factors and other determinants of health status such as sex, age, chronic diseases, obesity, and malnutrition(5, 6).

It is well known that malnutrition constitutes a risk factor for increased mortality and morbidity of several diseases(7). Protein and energy malnutrition, and other specific micronutrient deficiencies have been shown to manifest adverse effects in immunity and thereby exhibit poor prognosis of viral infections(8). Regarding micronutrients, the association between vitamin D (Vit D) deficiency and various diseases’ prevalence and/or severity, such as autoimmune disorders, diabetes and skeletal diseases have been adequately established in the past years(9). However, there is limited evidence with regards to Vit D concentration and preventive and/or curative mechanisms of SARS-CoV-2 infection(10). Recent studies have demonstrated the mechanisms for some possible interactions of serum vitamin D level with COVID-19 infections. Particularly, Vit D modulates the expression of angiotensin-converting enzyme 2 (ACE2), angiotensin (1-7) (Ang (1-7)) and mas receptor (MasR) axis and plays a crucial role in the protection against lung infection(11, 12). Thereby it acts as a renin-angiotensin system (RAS) inhibitor in treating COVID-19 patients with underlying comorbidities(13, 14), and can lead to a weakening of the cytokine storm and the Acute Respiratory Syndrome (ARS) risk among COVID-19 patients(15, 16). Moreover, Vit D is capable of exerting immunomodulatory function and improving mucosal defensive mechanisms and therefore an adequate serum concentration is more likely to be linked to a reduced mortality from respiratory diseases, such as COVID-19(17, 18).

In Italy, COVID-19 patients admitted to a Respiratory Intermediate Care Unit (RICU) with severe Vit D deficiency (<10 ng/ml), showed a ten-fold mortality rate compared to those with a serum Vit D concentration >10 ng/ml (p<0.05)(15). Similarly, in a prospective observational study of critically ill patients treated in a multidisciplinary Intensive Care Unit (ICU), it was revealed that all patients who died within 28 days, belonged to the low Vit D group(19). Munshi et al. also found that COVID-19 patients with poor prognosis had significantly lower serum concentrations of Vit D (p<0.001)(20).

It is evident that Vit D deficiency could be associated with the severity and mortality of COVID-19. Hence, the aim of this study was to investigate the relationship between country-specific prevalence of Vit D deficiency with regards to infection and mortality rates of COVID-19 among European countries, given the fewer variations in terms of biological, social and economic factors, including health care facilities.

Methods

Data sources and inclusion/exclusion criteria

Information on COVID-19 infections and mortalities, were retrieved from the Worldometer website, which provides real time statistics(1). This source contains data derived directly from official government reports of individual countries and/or indirectly through reliable local media resources. In addition, the latitude of each country was recorded from the CSGNetwork website, a reliable open source for the reference of close latitudes and longitudes of countries in the world(21).

Data on the prevalence of Vit D deficiency among these countries were extracted by conducting a comprehensive electronic search in PubMed® database. An advanced search was performed at the level of title/abstract by using keywords such as “Vitamin D” or “25-hydroxyvitamin D3”, combined with “deficiency”, “prevalence” or “status” and the name of each European country. The final search string and additional information about the search strategy are presented in Supplementary Table 1. The search was limited to articles published in the last five years (up to December, 23rd 2020) and included data only for adult population (>19 years). Following inclusion criteria were applied for the screening of found articles: a) Population-based studies; b) studies reporting non-institutional adults; c) studies defining Vit D deficiency as the serum concentration <20 ng/ml or <50 nmol/l; d) studies reporting Vit D deficiency as the prevalence of the sample population. In addition, conference proceedings, editorials, commentaries, book chapters/book reviews and studies confined to selective sample of community-dwelling people, such as pregnant women, elderly people, and patients with diagnosed illnesses were excluded. Finally, out of the screened articles for each country, the prevalence of Vit D deficiency data was retrieved from the most recently published study, including the most representative sample for each country.

Data extraction

For each European country, information on both COVID-19 infections and mortalities per 1M population as of December, 23rd 2020, were extracted from the Worldometer website(1) and the latitude was recorded from the CSGNetwork website(22). From the selected articles reporting Vit D deficiency among these countries, name of the first author, published year, sample size, age range of the study population and prevalence of Vit D deficiency were retrieved. All data were extracted by one reviewer (DB) using a standardized form and were checked for accuracy by a second reviewer (MC). Discrepancies in the extracted data were resolved by consensus.

Data analysis

The relationship between the prevalence of Vit D deficiency and other dependent variables, such as total number of COVID-19 infections and mortalities per 1M population were explored with correlation coefficients. Scatter plots were used to visually represent the correlations and the outcomes were evaluated by drawing a regression line. In the scatter plots, countries were differentiated according to their latitude following as; high latitude countries (50°N - 65°N) and middle latitude countries (35°N - 50°N). All countries were represented by a 3-letter country code according to the ISO (International Organization for Standardization) 3166, as per the Terminology Bulletin Country Names and the Country and Region Codes for Statistical Use maintained by the United Nations Statistics Divisions(23).

Results

A total of 14 European countries, satisfying the inclusion/exclusion criteria were selected for the analysis(24-37) (Table 1). The prevalence of Vit D deficiency ranged from 6.9-75.1% with the lowest and highest rates reported in Finland and France respectively. In more than half of the countries, the majority of the adult population was Vit D deficient (i.e. <20 ng/ml or <50 nmol/l). The size of study population which was used to retrieve data for the prevalence of Vit D deficiency varied from 222 (United Kingdom) to 74,235 subjects (Italy). As of December, 23rd 2020, in regard to the total number of COVID-19 infections per 1M of the total population, Finland reported the lowest with 6,147/1M, while France had the highest with 38,350/1M infections. In regard to the COVID-19 mortalities per 1M population, the lowest number, was documented in Norway (77 deaths/1M), whereas the highest number, was reported in Bosnia and Herzegovina (1,173 deaths/1M).

View this table:
Table 1:

The prevalence of vitamin D deficiency among 14 European countries.

Cases of COVID-19 infections per 1M population displayed a significant, strong positive correlation (r=0.82; p<0.001) with the prevalence of Vit D deficiency (Figure 1). Moreover, a 67% of the variation (R2=0.67) in total infections was attributed to the high prevalence of Vit D deficiency. In addition, a sharp upward trend was observed by the regression line resulted from the correlation analysis and most countries were scattered around the line, with Italy as the single outlier. The correlation effect noticeably improved to 0.90 after removing the outlier (Italy) from the analysis (r=0.90; p<0.001; R2=0.81).

Figure 1:
Figure 1:

Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 infections, as of December, 23rd 2020.

BIH: Bosnia and Herzegovina; DEU: Germany; DNK: Denmark; FIN: Finland; FRA: France; GBR: United Kingdom; GRC: Greece; IRE: Ireland; ITA: Italy; NOR: Norway; POL: Poland; PRT: Portugal; ROU: Romania; RUS: Russia.

▴ High latitude countries (50°N - 65°N); •-Middle latitude countries (35°N - 50°N).

Among the included European countries, the bottom and the top ends of the regression line were occupied by Finland, a high latitude country (50° N - 65° N) and France, a middle latitude country (35° N - 50° N) respectively, corresponding to the lowest and highest values for both the prevalence of Vit D deficiency and the number of COVID-19 infections per 1M population. High latitude countries showed greater variation in the prevalence of Vit D deficiency as well as in the number of COVID-19 infections. Particularly, the lower end was surrounded mostly by high latitude countries such as Finland, Norway and Ireland, indicating low prevalence of Vit D deficiency and low infection rate. Furthermore, other high latitude countries such as Russia, Denmark and Germany were clustered below the upper middle of the regression line with moderate prevalence of Vit D deficiency and moderate infection rate (Figure 1). However, all the middle latitude countries, except Greece, were located around the top end of the regression line, with higher values for both prevalence of Vit D deficiency and number of COVID-19 infections. In contrast, only two out of six high latitude countries (United Kingdom and Poland) were positioned around the top end of the regression line.

As illustrated in Figure 2, COVID-19 mortality per 1M population was also significantly positively correlated with the prevalence of Vit D deficiency (r=0.53; p=0.05). Most of the countries were scattered around the regression line, indicating 28% variability (R2=0.28) among the mortalities being due to the high prevalence of Vit D deficiency. Similarly to Figure 1, Italy was positioned as the outlier, and the correlation was increased markedly when it was removed from the analysis (r=0.70; p<0.001; R2=0.48). All the high latitude countries except United Kingdom, Poland and Germany, were located below the midpoint of the regression line, indicating the lower prevalence of Vit D deficiency and COVID-19 mortalities. On the contrary, all middle latitude countries, except Greece and Denmark, were found to be clustered around the top end of the line, denoting higher levels for both variables. Notably, in countries such as Denmark and Germany, moderate levels of mortality were observed, despite the higher levels of Vit D deficiency.

Figure 2:
Figure 2:

Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 mortalities, as of December, 23rd 2020.

BIH: Bosnia and Herzegovina; DEU: Germany; DNK: Denmark; FIN: Finland; FRA: France; GBR: United Kingdom; GRC: Greece; IRE: Ireland; ITA: Italy; NOR: Norway; POL: Poland; PRT: Portugal; ROU: Romania; RUS: Russia.

▴ High latitude countries (50°N - 65°N); •-Middle latitude countries (35°N - 50°N).

Discussion

Our analysis concluded that the prevalence of Vit D deficiency among the European population can be a potential risk factor for both COVID-19 infection and mortality rates. These findings are compatible with the outcomes of prior research works(38-40).

According to the outcomes of our study, in most of the European countries included in this analysis, more than 50% of the adult population was Vit D deficient, which constitutes an important factor to consider in the planning of public health preventive measures. One of the main reasons for the high prevalence of Vit D deficiency could be the urban lifestyle of the people residing in these countries (41). Additionally, the fluctuations of sunlight exposure among seasons could also impact the proportion of Vit D deficient population(42). Especially the negligible amount of sunlight during winter and cloud covers during summer could potentially reduce the cutaneous synthesis of Vit D in some less south located countries(41, 43). Furthermore, dietary sources of Vit D are limited and the obesity epidemic in the Europe, which is also related to poorer dietary choices, has worsened its deficiency(44).

The results of our analysis showed that most of the high latitude European countries (50°N - 65°N) had lower levels of infection and mortality rates, comparatively to the middle latitude ones (35°N - 50°N). This indicates that the latitude of these countries does not impact the prevalence of Vit D deficiency among their population. This result is in accordance with the findings of a study conducted in Honolulu, Hawaii (latitude of 21°N), where 51% of the population reported lower serum concentrations of Vit D, despite the theoretically sufficient UV exposure(45). Consequently, dietary intake of Vit D is considered to be the crucial factor related to the prevalence of Vit D deficiency among these European countries(46). However, adequate serum concentrations of Vit D cannot be easily reached only by dietary sources(47). Therefore, Vit D concentration improvement among the population of these countries should be targeted for as per the food fortification guidelines by the European Calcified Tissue Society (ECTS); at the same time enough attention should be paid to the monitoring of quality assurance in order to prevent intoxication(48).

Moreover, a similar pattern regarding the positions of the countries in the scatter plots of both COVID-19 infection and mortality rates against the prevalence of Vit D deficiency was observed. Italy was the single outlier in both scatter plots. This could be possible since it was one of the highly affected countries with serious clusters, soon after the breakout of COVID-19 pandemic(49), but later on both infection and mortality rates were reduced due to new treatment modalities(50). In addition, the position of Greece on the scatter plots was below the middle of the regression line, representing the moderate rates of COVID-19 infection and mortality, although the prevalence of Vit D deficiency was similar to Italy. The Greek government tried to confront the pandemic by acting at early stages through implementing a strict lockdown and also via effective communication with the public, especially in the context of the predominance of an elderly population and despite the fragile economy(51).

Differences between the plots were observed only for two countries, in particular Germany and Denmark. These two countries were found to have a relatively lower number of COVID-19 mortalities, despite of the moderate infection rates and the fact that more than 50% of their population presented Vit D deficiency. This outcome could be explained by several factors, such as advanced preventive and curative health policies, strict border closures, swift actions of the government and more importantly, by the early and adequate screening of COVID-19 among their population(52). Especially in Denmark up to 1,692,090 PCR tests/1M were performed, as of December, 23rd 2020(1).

Although only 14 European countries satisfied our inclusion criteria, the analysis included nearly 64% of the entire European population(3). Therefore, the results of our study can be generalized to most of the excluded European countries as well. Moreover, along with the majority of high income countries, upper-middle income countries, such as Russia and Bosnia and Herzegovina were also included in the analysis(53), reflecting the effect of economic status in the outcomes. However, most of the data on prevalence of Vit D deficiency among these countries were not generated from national level surveys. Therefore, the very recently published studies with most representative sample of each country population were carefully selected for the analysis. The screened studies were limited to adults (>19 years), as the severity of COVID-19 infections among children was mild(54), but one study included population of 16 years old as well(33). Furthermore, the overall prevalence of Vit D deficiency of the adult population was considered, even though there were considerable variations in the prevalence among different age groups. Similarly, the mean prevalence of Vit D deficiency was considered when different prevalence values were reported among various seasons. In addition, obesity constitutes a confounder of Vit D deficiency, COVID-19 infections and as well as mortalities, but in the outcomes of our study the effects of obesity in both variables were not reflected(55).

Governments should implement proper preventive measures to increase awareness among the populations on the risk of Vit D deficiency and on its role in severity and mortality of the COVID-19 pandemic. People should be encouraged to increase their dietary intake of Vit D, in addition to achieving adequate sunlight exposure. A preferred strategy could be Vit D fortification of foods with the intention to reduce the prevalence of Vit D deficiency. In addition, Vit D supplementation should be advised for those belonging to a high risk group of deficiency, such as new-borns, toddlers, pregnant women, elderly as well as non-Western immigrants(48). Moreover, regular country-wise assessment of Vit D status with standardized 25 (OH)D questionnaires should be encouraged as they can provide insights into future intervention therapies of diseases, such as COVID-19(56).

Conclusions

Significant positive correlations were detected between the total number of COVID-19 infections per 1M population (r=0.82; p<0.001) and mortality per 1M population (r=0.53; p=0.05) with respect to country-specific prevalence of Vit D deficiency among 14 European countries. Most of the high latitude European countries showed less values for both COVID-19 infection and mortality rates, while most of middle latitude countries showed higher values for both variables. Germany and Denmark had lower mortality rates despite moderate levels of COVID-19 infections and prevalence of Vit D deficiency, due to swift government actions, strict border closures and high level of testing.

Data Availability

COVID-19 infections and mortalities per million population were extracted from the Worldometer website, whereas the latitude of each country was taken from the CSGNetwork website

https://www.worldometers.info/coronavirus/

Acknowledgements

We would like to most cordially thank Prof. Ranil Jayawardena and Dr. Dhanushya T Jeyakumar for their important contribution in all stages of the manuscript preparation.

Footnotes

  • Financial Support: This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

  • Conflict of Interest: None.

  • Authorship: Conceptualization and methodology, data collection, validation and analysis, writing-Original draft, review and editing: DB, MC

Abbreviations

1M
One million
25(OH)D
25-hydroxyvitamin D3
ACE2
Angiotensin-Converting Enzyme 2
Ang (1-7)
Angiotensin (1-7)
ARS
Acute Respiratory Syndrome
COVID-19
Coronavirus disease 2019
ECTS
European Calcified Tissue Society
ICU
Intensive Care Unit
ISO
International Organization for Standardization
MasR
Mas Receptor
PCR
Polymerase Chain Reaction
RAS
Renin - Angiotensin System
RICU
Respiratory Intermediate Care Unit
SARS-CoV-2
Severe Acute Respiratory Syndrome Coronavirus
UV
Ultraviolet
UVB
Ultraviolet B
Vit D
Vitamin D

References

  1. 1.↵
    (2020) Worldometer, COVID-19 Coronovirus Pandemic https://www.worldometers.info/coronavirus/ (accessed 24 Dec 2020 2020)
  2. 2.↵
    Zhu H, Wei L Niu P (2020) The novel coronavirus outbreak in Wuhan, China. Global health research and policy 5, 1–3.
    OpenUrl
  3. 3.↵
    (2020) WHO Coronovirus Disease (COVID-19) Dashboard. Situation by WHO Region. https://covid19.who.int/ (accessed 24 December 2020
  4. 4.↵
    Chaudhry R, Dranitsaris G, Mubashir T et al. (2020) A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. EClinicalMedicine 25, 100464.
    OpenUrl
  5. 5.↵
    Fedele D, De Francesco A, Riso S et al. (2020) Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. Nutrition (Burbank, Los Angeles County, Calif) 81, 111016–111016.
    OpenUrl
  6. 6.↵
    Clark A, Jit M, Warren-Gash C et al. (2020) Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health 8, e1003–e1017.
    OpenUrl
  7. 7.↵
    Söderström L, Rosenblad A, Adolfsson ET et al. (2017) Malnutrition is associated with increased mortality in older adults regardless of the cause of death. British Journal of Nutrition 117, 532–540.
    OpenUrl
  8. 8.↵
    Jayawardena R, Sooriyaarachchi P, Chourdakis M et al. (2020) Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
  9. 9.↵
    Wacker M & Holick MF (2013) Vitamin D—effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 5, 111–148.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Ali N (2020) Role of vitamin D in preventing of COVID-19 infection, progression and severity. Journal of infection and public health.
  11. 11.↵
    Cui C, Xu P, Li G et al. (2019) Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of renin-angiotensin system. Redox biology 26, 101295.
    OpenUrl
  12. 12.↵
    Li Y, Zeng Z, Cao Y et al. (2016) Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways. Scientific reports 6, 27911.
    OpenUrl
  13. 13.↵
    Kuster GM, Pfister O, Burkard T et al. (2020) SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? European Heart Journal.
  14. 14.↵
    Li YC, Qiao G, Uskokovic M et al. (2004) Vitamin D: a negative endocrine regulator of the renin– angiotensin system and blood pressure. The Journal of steroid biochemistry and molecular biology 89, 387–392.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Carpagnano GE, Di Lecce V, Quaranta VN et al. (2020) Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. Journal of endocrinological investigation, 1–7.
  16. 16.↵
    Daneshkhah A, Agrawal V, Eshein A et al. (2020) Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients. Aging Clinical and Experimental Research 32, 2141–2158.
    OpenUrl
  17. 17.↵
    Baeke F, Takiishi T, Korf H et al. (2010) Vitamin D: modulator of the immune system. Current opinion in pharmacology 10, 482–496.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    Barlow PG, Beaumont PE, Cosseau C et al. (2010) The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. American journal of respiratory cell and molecular biology 43, 692–702.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Vassiliou AG, Jahaj E, Pratikaki M et al. (2020) Low 25-Hydroxyvitamin D Levels on Admission to the Intensive Care Unit May Predispose COVID-19 Pneumonia Patients to a Higher 28-Day Mortality Risk: A Pilot Study on a Greek ICU Cohort. Nutrients 12, 3773.
    OpenUrl
  20. 20.↵
    Munshi R, Hussein MH, Toraih EA et al. (2020) Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. Journal of medical virology.
  21. 21.↵
    Haywood LJ, Khan AH, Bornheimer J et al. (1997) Recurrent myocardial infarction with patent coronary arteries. Journal of the National Medical Association 89, 415–420.
    OpenUrlPubMed
  22. 22.↵
    Ulmer HE, Knapp WH Scharer K (1975) EXERCISE TESTS AND ECHOCARDIOGRAPHY IN CHILDREN WITH CHRONIC RENAL-FAILURE -CRF. Pediatric Research 9, 855.
    OpenUrl
  23. 23.↵
    Cade P (1997) How exercise can change “disability” to “ability” in the ESRD patient. Nephrology news & issues 11, 55–56.
    OpenUrl
  24. 24.↵
    Sokolovic S, Alimanovic-Alagic R, Dzananovic L et al. (2017) Vitamin D status in Bosnia and Herzegovina: the cross-sectional epidemiological analysis. Osteoporos Int 28, 1021–1025.
    OpenUrl
  25. 25.
    Hansen L, Tjønneland A, Køster B et al. (2018) Vitamin D Status and Seasonal Variation among Danish Children and Adults: A Descriptive Study. Nutrients 10.
  26. 26.
    Adebayo FA, Itkonen ST, Lilja E et al. (2020) Prevalence and determinants of vitamin D deficiency and insufficiency among three immigrant groups in Finland: evidence from a population-based study using standardised 25-hydroxyvitamin D data. Public Health Nutr 23, 1254–1265.
    OpenUrl
  27. 27.
    Deplanque X, Wullens A Norberciak L (2017) [Prevalence and risk factors of vitamin D deficiency in healthy adults aged 18-65 years in northern France]. Rev Med Interne 38, 368–373.
    OpenUrl
  28. 28.
    Rabenberg M, Scheidt-Nave C, Busch MA et al. (2018) Implications of standardization of serum 25-hydroxyvitamin D data for the evaluation of vitamin D status in Germany, including a temporal analysis. BMC Public Health 18, 845.
    OpenUrl
  29. 29.
    Dimakopoulos I, Magriplis E, Mitsopoulou AV et al. (2019) Association of serum vitamin D status with dietary intake and sun exposure in adults. Clin Nutr ESPEN 34, 23–31.
    OpenUrl
  30. 30.
    Griffin TP, Wall D, Blake L et al. (2020) Higher risk of vitamin D insufficiency/deficiency for rural than urban dwellers. The Journal of Steroid Biochemistry and Molecular Biology 197, 105547.
    OpenUrl
  31. 31.
    Giuliani S, Barbieri V, Di Pierro AM et al. (2019) LC-MS/MS based 25(OH)D status in a large Southern European outpatient cohort: gender- and age-specific differences. Eur J Nutr 58, 2511–2520.
    OpenUrl
  32. 32.
    Petrenya N, Lamberg-Allardt C, Melhus M et al. (2020) Vitamin D status in a multi-ethnic population of northern Norway: the SAMINOR 2 Clinical Survey. Public Health Nutr 23, 1186–1200.
    OpenUrl
  33. 33.↵
    Pludowski P, Ducki C, Konstantynowicz J et al. (2016) Vitamin D status in Poland. Pol Arch Med Wewn 126, 530–539.
    OpenUrl
  34. 34.
    Duarte C, Carvalheiro H, Rodrigues AM et al. (2020) Prevalence of vitamin D deficiency and its predictors in the Portuguese population: a nationwide population-based study. Arch Osteoporos 15, 36.
    OpenUrl
  35. 35.
    Niculescu DA, Capatina CAM, Dusceac R et al. (2017) Seasonal variation of serum vitamin D levels in Romania. Arch Osteoporos 12, 113.
    OpenUrlPubMed
  36. 36.
    Karonova T, Andreeva A, Nikitina I et al. (2016) Prevalence of Vitamin D deficiency in the North-West region of Russia: A cross-sectional study. J Steroid Biochem Mol Biol 164, 230–234.
    OpenUrl
  37. 37.↵
    Jolliffe DA, Hanifa Y, Witt KD et al. (2016) Environmental and genetic determinants of vitamin D status among older adults in London, UK. J Steroid Biochem Mol Biol 164, 30–35.
    OpenUrl
  38. 38.↵
    De Smet D, De Smet K, Herroelen P et al. (2020) Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. MedRxiv.
  39. 39.
    Laird E, Rhodes J Kenny RA (2020) Vitamin D and inflammation: potential implications for severity of Covid-19. Ir Med J 113, 81.
    OpenUrlPubMed
  40. 40.↵
    Radujkovic A, Hippchen T, Tiwari-Heckler S et al. (2020) Vitamin D deficiency and outcome of COVID-19 patients. Nutrients 12, 2757.
    OpenUrl
  41. 41.↵
    Mendes MM, Darling AL, Hart KH et al. (2019) Impact of high latitude, urban living and ethnicity on 25-hydroxyvitamin D status: A need for multidisciplinary action? The Journal of Steroid Biochemistry and Molecular Biology 188, 95–102.
    OpenUrlPubMed
  42. 42.↵
    Schramm S, Lahner H, Jöckel K-H et al. (2017) Impact of season and different vitamin D thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of caution. Endocrine 56, 658–666.
    OpenUrl
  43. 43.↵
    Webb A, Kift R, Durkin M et al. (2010) The role of sunlight exposure in determining the vitamin D status of the UK white adult population. British Journal of Dermatology 163, 1050–1055.
    OpenUrlCrossRefPubMed
  44. 44.↵
    Snijder MB, van Dam RM, Visser M et al. (2005) Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. The Journal of Clinical Endocrinology & Metabolism 90, 4119–4123.
    OpenUrl
  45. 45.↵
    Binkley N, Novotny R, Krueger D et al. (2007) Low vitamin D status despite abundant sun exposure. The Journal of Clinical Endocrinology&Metabolism 92, 2130–2135.
    OpenUrl
  46. 46.↵
    van Schoor N & Lips P (2018) Worldwide vitamin D status. In Vitamin D, pp. 15–40: Elsevier.
  47. 47.↵
    Kasapidou E, Oikonomidou A Chourdakis M (2018) Vitamin D status among Mediterranean regions. Hippokratia 22, 191.
    OpenUrl
  48. 48.↵
    Lips P, Cashman KD, Lamberg-Allardt C et al. (2019) Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. European Journal of Endocrinology 180, P23-P54.
    OpenUrl
  49. 49.↵
    Livingston E&Bucher K (2020) Coronavirus disease 2019 (COVID-19) in Italy. Jama 323, 1335–1335.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Drozdzal S, Rosik J, Lechowicz K et al. (2020) FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug resistance updates, 100719.
  51. 51.↵
    Perrigo B&Hincks J (2020) Greece has an Elderly Population and a Fragile Economy. How Has it Escaped the Worst of the Coronavirus so Far?: Time. Disponible en: https://time.com/5824836/greece-coronavirus.
  52. 52.↵
    Stafford N (2020) Covid-19: Why Germany’s case fatality rate seems so low. Bmj 369.
  53. 53.↵
    Ono M (1979) Exercise Capacity of Children with Chronic Renal Failure (Part 3) (Permissible exercise strength the patients). Japanese Journal of Nephrology 21, 1105–1111.
    OpenUrl
  54. 54.↵
    Brodin P (2020) Why is COVID-19 so mild in children? Acta Paediatrica 109, 1082–1083.
    OpenUrl
  55. 55.↵
    Jayawardena R, Jeyakumar DT, Misra A et al. (2020) Obesity: A potential risk factor for infection and mortality in the current COVID-19 epidemic. Diabetes&Metabolic Syndrome: Clinical Research&Reviews 14, 2199–2203.
    OpenUrl
  56. 56.↵
    Castillo ME, Costa LME, Barrios JMV et al. (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. The Journal of steroid biochemistry and molecular biology 203, 105751.
    OpenUrlCrossRefPubMed
Back to top
Posted January 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Is vitamin D deficiency associated with the COVID-19 epidemic in Europe?
Dimitra Rafailia Bakaloudi, Michail Chourdakis
medRxiv 2021.01.28.21250673; doi: https://doi.org/10.1101/2021.01.28.21250673
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area